Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4006 |
Name | bladder urothelial carcinoma |
Definition | A bladder carcinoma that has_material_basis_in transitional cells located_in the lining of the bladder. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma bladder urothelial carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR3 mutant | Infigratinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 mutant | Dovitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 S249C | Dovitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 mutant | Erdafitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 R248C | Erdafitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 S249C | Erdafitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 Y373C | Erdafitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 G370C | Erdafitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 A391E | Fexagratinib | bladder urothelial carcinoma | predicted - sensitive | detail... |
HRAS Q61R | Tipifarnib | bladder urothelial carcinoma | predicted - sensitive | detail... |
HRAS V29Cfs*19 | Tipifarnib | bladder urothelial carcinoma | predicted - sensitive | detail... |
PIK3CA M1043I PIK3CA amp | Everolimus | bladder urothelial carcinoma | predicted - sensitive | detail... |
FGFR3 Y373C | Anlotinib + Sintilimab | bladder urothelial carcinoma | predicted - sensitive | detail... |
CDKN2A inact mut | unspecified immune checkpoint inhibitor | bladder urothelial carcinoma | decreased response | detail... |
CDKN2A del | unspecified immune checkpoint inhibitor | bladder urothelial carcinoma | decreased response | detail... |
FGFR3 act mut | Erdafitinib | bladder urothelial carcinoma | sensitive | detail... |
FGFR3 S249C PIK3CA E545K | Erdafitinib | bladder urothelial carcinoma | predicted - resistant | detail... |
FGFR3 S249C PIK3CA E545K | Futibatinib | bladder urothelial carcinoma | predicted - resistant | detail... |
FGFR3 S249C FGFR3 V553M | Erdafitinib | bladder urothelial carcinoma | predicted - resistant | detail... |
FGFR3 Y373C FGFR3 N540K FGFR3 V555L FGFR3 L608V | Futibatinib | bladder urothelial carcinoma | predicted - resistant | detail... |
FGFR3 Y373C | Pemigatinib | bladder urothelial carcinoma | predicted - sensitive | detail... |
FGFR3 S249C TSC1 Q830* | Erdafitinib | bladder urothelial carcinoma | predicted - resistant | detail... |
FGFR3 S249C TSC1 S561fs | Erdafitinib | bladder urothelial carcinoma | predicted - sensitive | detail... |
FGFR3 S249C FGFR3 E587Q FGFR3 amp PIK3CA E726K TSC1 S561fs | Erdafitinib | bladder urothelial carcinoma | predicted - resistant | detail... |
FGFR3 S249C | Pembrolizumab + Pemigatinib | bladder urothelial carcinoma | predicted - sensitive | detail... |
FGFR3 S249C | R3-altibody | bladder urothelial carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00942331 | Phase III | Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | Completed | USA | 1 |
NCT01108055 | Phase II | Paclitaxel + Pazopanib | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | Completed | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01215136 | Phase II | Everolimus Paclitaxel | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | Terminated | USA | 0 |
NCT01326871 | Phase Ib/II | ALT-801 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT01438112 | Phase II | Valrubicin Mitomycin C CG0070 Interferon gamma Gemcitabine | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND) | Terminated | USA | 0 |
NCT01625260 | Phase Ib/II | ALT-801 ALT-801 + Gemcitabine | A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer | Terminated | USA | 0 |
NCT01780545 | Phase II | Apatorsen Docetaxel | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | Completed | USA | 0 |
NCT01916109 | Phase II | Carboplatin + Gemcitabine + Panitumumab | Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | Terminated | USA | 0 |
NCT02009332 | Phase Ib/II | Sirolimus | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | Completed | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Completed | USA | CAN | 0 |
NCT02108652 | Phase II | Atezolizumab | A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT02122172 | Phase II | Afatinib | Afatinib in Advanced Refractory Urothelial Cancer | Terminated | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02197897 | Phase II | Tamoxifen | Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors | Completed | USA | 0 |
NCT02236195 | Phase II | Mocetinostat | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | Completed | USA | 0 |
NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | ROU | POL | ITA | BGR | 0 |
NCT02256436 | Phase III | Pembrolizumab | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | Completed | 0 | |
NCT02300610 | Phase I | Cisplatin + Gemcitabine Enzalutamide | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | Completed | USA | 0 |
NCT02302807 | Phase III | Paclitaxel Vinorelbine Atezolizumab Docetaxel | A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | TUR | SWE | SVN | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 6 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | NLD | FRA | 1 |
NCT02324582 | Phase I | Pembrolizumab | MK-3475/BCG in High Risk Superficial Bladder Cancer | Completed | USA | 0 |
NCT02334527 | Phase II | Palbociclib | Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy | Terminated | USA | 0 |
NCT02335424 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) | Completed | 0 | |
NCT02351739 | Phase II | Pembrolizumab Acalabrutinib | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer | Completed | USA | 0 |
NCT02365766 | Phase Ib/II | Cisplatin Pembrolizumab Gemcitabine | Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT02365818 | Phase II | CG0070 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure | Completed | USA | 0 |
NCT02387996 | Phase II | Nivolumab | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | Completed | USA | SWE | POL | ITA | FIN | ESP | DEU | CZE | BEL | AUS | 1 |
NCT02401542 | Phase Ib/II | Docetaxel + Vofatamab Vofatamab Docetaxel | Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21) | Terminated | USA | TUR | SWE | ITA | GBR | ESP | CZE | 2 |
NCT02426125 | Phase III | Ramucirumab Docetaxel | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | Completed | USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 6 |
NCT02437370 | Phase I | Pembrolizumab Gemcitabine Docetaxel | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | Completed | USA | 0 |
NCT02443324 | Phase I | Pembrolizumab + Ramucirumab | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT02449239 | Phase III | Oportuzumab monatox | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG | Completed | USA | CAN | 0 |
NCT02450331 | Phase III | Atezolizumab | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) | Terminated | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUS | 7 |
NCT02451423 | Phase II | Atezolizumab | Study of MPDL3280A in Bladder Cancer | Completed | USA | 0 |
NCT02459119 | Phase II | Regorafenib | Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) | Completed | USA | 0 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated | USA | 1 |
NCT02496208 | Phase I | Ipilimumab Cabozantinib + Nivolumab | Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors | Active, not recruiting | USA | 0 |
NCT02500121 | Phase II | Pembrolizumab | Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer | Completed | USA | 0 |
NCT02516241 | Phase III | Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab | Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | 7 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02553642 | Phase II | Nivolumab Ipilimumab | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Completed | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02567409 | Phase II | Cisplatin + Gemcitabine Berzosertib + Cisplatin + Gemcitabine | Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT02581982 | Phase II | Pembrolizumab Paclitaxel | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT02589717 | FDA approved | Atezolizumab | An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy | Approved for marketing | USA | 0 |
NCT02608125 | Phase I | PRN1371 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | Terminated | USA | ESP | 0 |
NCT02612194 | Phase II | Crizotinib | LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer | Terminated | USA | 0 |
NCT02619253 | Phase Ib/II | Pembrolizumab + Vorinostat | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | Completed | USA | 0 |
NCT02621151 | Phase II | Pembrolizumab Gemcitabine | Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder | Active, not recruiting | USA | 0 |
NCT02625961 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) | Recruiting | USA | TUR | NLD | ITA | FRA | FIN | ESP | BRA | AUS | 2 |
NCT02632409 | Phase III | Nivolumab | A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma | Active, not recruiting | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02657486 | Phase 0 | Infigratinib | BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder | Active, not recruiting | USA | 0 |
NCT02662062 | Phase II | Cisplatin + Pembrolizumab | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer (PCR-MIB) | Active, not recruiting | AUS | 0 |
NCT02690558 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | Active, not recruiting | USA | 0 |
NCT02710396 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Genetic Predictors of Benefit to Pembrolizumab | Terminated | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT02792192 | Phase Ib/II | Atezolizumab + BCG solution Atezolizumab | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants | Terminated | USA | 0 |
NCT02807636 | Phase III | Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine | The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy | Completed | USA | TUR | SVN | ROU | POL | NLD | ITA | ISR | GRC | GBR | FIN | EST | ESP | CZE | CAN | BRA | BEL | AUS | 17 |
NCT02812420 | Phase I | Durvalumab + Tremelimumab | Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy | Active, not recruiting | USA | 0 |
NCT02844816 | Phase II | Atezolizumab | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02845323 | Phase II | Urelumab Nivolumab + Urelumab | Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder | Active, not recruiting | USA | 0 |
NCT02853305 | Phase III | Pembrolizumab Carboplatin + Cisplatin + Gemcitabine | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | Completed | 0 | |
NCT02872714 | Phase II | Pemigatinib | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | Completed | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | BEL | 1 |
NCT02891161 | Phase Ib/II | Durvalumab | Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | Terminated | USA | 0 |
NCT02897765 | Phase I | Nivolumab NEO-PV-01 + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Completed | USA | 0 |
NCT02901548 | Phase II | Durvalumab | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | Terminated | USA | 0 |
NCT02925533 | Phase I | Pembrolizumab + Vofatamab | Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | Terminated | USA | 0 |
NCT02989064 | Phase I | MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers | Completed | USA | ESP | CAN | 0 | |
NCT02989584 | Phase Ib/II | Atezolizumab + Cisplatin + Gemcitabine | A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03022825 | Phase II | BCG solution + Nogapendekin alfa inbakicept | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03093922 | Phase II | Atezolizumab + Cisplatin + Gemcitabine | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03106610 | Phase I | Nivolumab | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | Terminated | USA | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03150836 | Phase II | Durvalumab Durvalumab + Tremelimumab | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | Withdrawn | USA | 0 |
NCT03170960 | Phase Ib/II | Atezolizumab + Cabozantinib | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT03171493 | Phase I | MV-NIS | Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy | Completed | USA | 0 |
NCT03237780 | Phase II | Atezolizumab Atezolizumab + Eribulin | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT03258593 | Phase I | Durvalumab + Oportuzumab monatox | Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | Completed | USA | 0 |
NCT03272217 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | Terminated | USA | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03319745 | Phase II | Pembrolizumab | A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy | Completed | USA | 0 |
NCT03324282 | Phase II | Cisplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma (GCISAVE) | Terminated | FRA | 0 |
NCT03359239 | Phase I | Atezolizumab + PGV 001 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | Completed | USA | 0 |
NCT03361865 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) | Completed | USA | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 5 |
NCT03374488 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma | Completed | USA | TUR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 4 |
NCT03379909 | Phase II | Metformin | Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer (TROJAN) | Recruiting | NLD | 0 |
NCT03397394 | Phase II | Rucaparib | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03410693 | Phase II | Docetaxel Vinflunine Paclitaxel Rogaratinib | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) | Completed | USA | SWE | SVK | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 8 |
NCT03421652 | Phase II | Nivolumab | Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy | Completed | USA | 0 |
NCT03425201 | Phase Ib/II | Cabozantinib + Niraparib | Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) | Completed | ESP | 0 |
NCT03451331 | Phase II | Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT03459846 | Phase II | Durvalumab + Olaparib Durvalumab | A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) | Active, not recruiting | USA | ESP | CAN | 4 |
NCT03472274 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Paclitaxel Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO) | Completed | ESP | 0 |
NCT03473730 | Phase I | Daratumumab | Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03473756 | Phase Ib/II | Atezolizumab Atezolizumab + Rogaratinib | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) | Completed | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT03498196 | Phase Ib/II | Avelumab | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | Terminated | USA | 0 |
NCT03502681 | Phase I | Avelumab + Eribulin | A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients | Terminated | USA | 0 |
NCT03502785 | Phase Ib/II | Atezolizumab + INO-5401 + INO-9012 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | Active, not recruiting | USA | 0 |
NCT03513952 | Phase II | Atezolizumab + CYT107 Atezolizumab | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | Completed | USA | 0 |
NCT03517956 | Phase I | Copanlisib + Rogaratinib | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) | Completed | USA | ESP | DEU | BEL | 2 |
NCT03518320 | Phase I | Gemcitabine + Nivolumab | Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer | Terminated | USA | 0 |
NCT03519256 | Phase II | Linrodostat + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + Linrodostat + Nivolumab | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) | Terminated | USA | NLD | ITA | GBR | FRA | ESP | CAN | BRA | AUS | ARG | 5 |
NCT03520231 | Phase II | Carboplatin + Cisplatin + Denosumab + Gemcitabine Carboplatin + Cisplatin + Gemcitabine | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | Completed | CAN | 0 |
NCT03520491 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | Recruiting | USA | 0 |
NCT03529890 | Phase II | Nivolumab | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (RACE IT) | Unknown status | DEU | 0 |
NCT03532451 | Phase I | Lirilumab + Nivolumab Nivolumab | Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807) | Completed | USA | 0 |
NCT03557918 | Phase II | Tremelimumab | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT03575013 | Phase I | Avelumab + Docetaxel | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT03601455 | Phase II | Durvalumab + Tremelimumab Durvalumab | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03617913 | Phase II | Avelumab + Cisplatin + Fluorouracil + Mitomycin C | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | Completed | USA | 0 |
NCT03620435 | Phase II | Atezolizumab | Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer | Unknown status | CAN | 0 |
NCT03628716 | Phase II | Atezolizumab + CV301 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed | USA | 0 |
NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | USA | ESP | CAN | AUS | 0 |
NCT03674424 | Phase II | Avelumab + Gemcitabine + Paclitaxel Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine Avelumab Avelumab + Cisplatin + Gemcitabine | Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA) | Active, not recruiting | FRA | BEL | 0 |
NCT03682068 | Phase III | Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | CAN | BRA | BGR | AUS | ARG | 9 |
NCT03697850 | Phase II | Atezolizumab | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (BladderSpar) | Active, not recruiting | FRA | 0 |
NCT03711032 | Phase III | BCG solution + Pembrolizumab BCG solution | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | Active, not recruiting | USA | TUR | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | 10 |
NCT03732677 | Phase III | Cisplatin + Gemcitabine Cisplatin + Durvalumab + Gemcitabine | Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 7 |
NCT03737123 | Phase II | Atezolizumab + Carboplatin + Gemcitabine | Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | Terminated | USA | 0 |
NCT03768570 | Phase II | Durvalumab | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | Active, not recruiting | GBR | ESP | CAN | 0 |
NCT03773666 | Phase I | Durvalumab + Oleclumab Durvalumab | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | Completed | USA | 0 |
NCT03775265 | Phase III | Atezolizumab + Cisplatin + Mitomycin C Fluorouracil + Mitomycin C Atezolizumab + Gemcitabine + Mitomycin C Gemcitabine + Mitomycin C Atezolizumab + Fluorouracil + Mitomycin C Cisplatin + Mitomycin C | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03799835 | Phase III | Atezolizumab + BCG solution BCG solution | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN) | Active, not recruiting | FRA | ESP | BEL | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ISR | FRA | ESP | CAN | BEL | AUS | 4 |
NCT03824691 | Phase II | Cabozantinib + Durvalumab | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA) | Unknown status | ITA | 0 |
NCT03854721 | Phase I | VAX014 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | Completed | USA | 0 |
NCT03866382 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors | Recruiting | USA | 1 |
NCT03869190 | Phase Ib/II | Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) | Active, not recruiting | USA | GRC | GBR | FRA | ESP | 2 |
NCT03898180 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | Completed | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | ARG | 5 |
NCT03912818 | Phase II | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine Carboplatin + Durvalumab + Gemcitabine | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | Terminated | USA | 0 |
NCT03914794 | Phase II | Pemigatinib | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | Recruiting | USA | 0 |
NCT03915405 | Phase I | Avelumab + KHK2455 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Terminated | USA | ESP | 0 |
NCT03934814 | Phase I | Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Completed | USA | 1 |
NCT03935347 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | Withdrawn | USA | 0 |
NCT03978624 | Phase II | Pembrolizumab Entinostat + Pembrolizumab | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03980041 | Phase II | Nivolumab Eganelisib + Nivolumab | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | Completed | USA | POL | ITA | FRA | ESP | CZE | 1 |
NCT04004442 | Phase II | AVB-S6-500 + Avelumab | Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN) | Active, not recruiting | USA | 0 |
NCT04040725 | Phase II | Rogaratinib | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | Withdrawn | 0 | |
NCT04045613 | Phase Ib/II | Derazantinib Atezolizumab + Derazantinib | Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02) | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUT | AUS | 1 |
NCT04064190 | Phase II | Durvalumab + Vactosertib | Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Not yet recruiting | USA | 0 |
NCT04066595 | Phase II | Cabozantinib | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. (CabUC) | Terminated | DEU | 0 |
NCT04073160 | Phase I | Durvalumab Durvalumab + Tremelimumab | TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) | Withdrawn | USA | 0 |
NCT04109092 | Phase I | E7766 | A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 | Withdrawn | USA | 0 |
NCT04134000 | Phase I | Atezolizumab + BCG solution | Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE) | Active, not recruiting | ESP | 0 |
NCT04143711 | Phase Ib/II | DF1001 DF1001 + Pembrolizumab | Study of DF1001 in Patients With Advanced Solid Tumors | Recruiting | USA | NLD | FRA | DNK | BEL | 0 |
NCT04164082 | Phase II | Gemcitabine + Pembrolizumab | Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | Recruiting | USA | 2 |
NCT04165317 | Phase III | BCG solution + PF-06801591 BCG solution | Study of PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer. (B8011006) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT04179110 | Phase II | Pembrolizumab + Ramucirumab | Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor | Withdrawn | USA | 0 |
NCT04216290 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Active, not recruiting | USA | 0 |
NCT04276376 | Phase II | Atezolizumab + Rucaparib | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) | Suspended | FRA | 0 |
NCT04289779 | Phase II | Atezolizumab + Cabozantinib | Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE) (ABATE) | Active, not recruiting | USA | 0 |
NCT04294277 | Phase II | Pemigatinib | Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS) | Terminated | ITA | 0 |
NCT04349280 | Phase I | Bintrafusp alfa | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | Terminated | USA | NLD | FRA | ESP | CAN | 0 |
NCT04383938 | Phase Ib/II | APR-246 + Pembrolizumab | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | Completed | USA | 0 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04430036 | Phase II | Balstilimab + Cisplatin + Gemcitabine + Zalifrelimab | AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer | Terminated | USA | 0 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT04501094 | Phase II | Bintrafusp alfa | A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma | Terminated | USA | 0 |
NCT04506554 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | Active, not recruiting | USA | 0 |
NCT04602078 | Phase II | Atezolizumab + Cisplatin + Gemcitabine | Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA) | Completed | ESP | 0 |
NCT04608045 | Phase I | CPX-POM | Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04610671 | Phase I | CG0070 + Nivolumab | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | Active, not recruiting | USA | 0 |
NCT04624399 | Phase II | Atezolizumab | Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer (ABACUS-2) | Recruiting | GBR | 0 |
NCT04630730 | Phase II | BCG solution Atezolizumab + Cisplatin + Gemcitabine | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | Recruiting | CHE | 0 |
NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Active, not recruiting | USA | 0 |
NCT04660344 | Phase III | Atezolizumab | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) | Active, not recruiting | USA | TUR | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | BRA | BEL | ARG | 9 |
NCT04678362 | Phase II | Avelumab + Talazoparib | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (TALASUR) | Recruiting | FRA | 0 |
NCT04690699 | Phase Ib/II | PVSRIPO + unspecified PD-1 antibody | LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04701918 | Phase II | Pembrolizumab | Pembrolizumab And Cryoablation In Urothelial Carcinoma | Recruiting | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04724018 | Phase I | Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy | Sacituzumab Govitecan Plus EV in Metastatic UC | Active, not recruiting | USA | 0 |
NCT04779151 | Phase II | Dostarlimab-gxly + Niraparib | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) | Suspended | FRA | 0 |
NCT04813107 | Phase Ib/II | APL-1202 + Tislelizumab Tislelizumab | A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE) | Unknown status | USA | 1 |
NCT04848519 | Phase II | Pembrolizumab + Propranolol | Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer | Recruiting | USA | 0 |
NCT04871529 | Phase II | Avelumab + Carboplatin + Gemcitabine | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) | Suspended | USA | 0 |
NCT04876313 | Phase II | Nab-paclitaxel + Nivolumab | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo) | Recruiting | ITA | 0 |
NCT04879329 | Phase II | Disitamab vedotin Disitamab vedotin + Pembrolizumab | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Recruiting | USA | ITA | ISR | GBR | ESP | CAN | BEL | AUS | ARG | 2 |
NCT04919512 | Phase II | Cetrelimab + TAR-200 Cetrelimab | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | BEL | 1 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04953104 | Phase II | Nivolumab | Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | Recruiting | USA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04963153 | Phase I | Enfortumab vedotin-ejfv + Erdafitinib | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | Recruiting | USA | CAN | 0 |
NCT04972253 | Phase I | Infigratinib | Phase I BLASST-3 Trial ((BLASST)-3) | Withdrawn | 0 | |
NCT05077709 | Phase II | IO102-IO103 + Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Active, not recruiting | USA | GBR | ESP | 0 |
NCT05085977 | Phase I | TARA-002 | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1) | Active, not recruiting | USA | ROU | 2 |
NCT05085990 | Phase I | TARA-002 | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1) | Completed | USA | 0 |
NCT05092958 | Phase III | Avelumab + Cabozantinib Avelumab | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | Active, not recruiting | USA | CAN | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05120622 | Phase Ib/II | Durvalumab + Tremelimumab | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau) | Withdrawn | CAN | 0 |
NCT05137262 | Phase II | Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine Cisplatin + Doxorubicin + Methotrexate + Vinblastine | A PHASE II MULTICENTER STUDY OF CHEMOTHERAPY VERSUS CHEMOTHERAPY PLUS DURVALUMAB (MEDI 4736) IN PATIENTS WITH LYMPH NODE POSITIVE UROTHELIAL CARCINOMA OF THE BLADDER | Recruiting | USA | 0 |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT05200988 | Phase II | Mitomycin C Ipilimumab + Nivolumab Capecitabine Fluorouracil | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade) | Active, not recruiting | NLD | 0 |
NCT05203913 | Phase II | Cisplatin + Nab-paclitaxel + Nivolumab | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer (CNN-BC) | Recruiting | ITA | 0 |
NCT05219435 | Phase II | Ipilimumab + Nivolumab | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) | Recruiting | ESP | 0 |
NCT05239624 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | Recruiting | USA | 0 |
NCT05316155 | Phase I | Erdafitinib | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Recruiting | USA | NLD | ESP | DEU | 1 |
NCT05406713 | Phase II | Pembrolizumab | Pembrolizumab in MIBC | Recruiting | USA | 0 |
NCT05562830 | Phase Ib/II | VLS-101 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | Active, not recruiting | USA | ISR | ESP | DNK | AUS | 2 |
NCT05564416 | Phase II | Erdafitinib Atezolizumab + Erdafitinib | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | Withdrawn | 0 | |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05894447 | Phase I | Naptumomab estafenatox + Pembrolizumab Obinutuzumab | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | Withdrawn | USA | 0 |
NCT05911295 | Phase III | Disitamab vedotin + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Recruiting | USA | ITA | ISR | FRA | ESP | CAN | BRA | AUS | ARG | 5 |
NCT05943106 | Phase III | BCG solution + Durvalumab | BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO) | Recruiting | USA | 0 |
NCT05987241 | Phase II | Nivolumab Nivolumab + Relatlimab | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study | Recruiting | USA | 0 |
NCT06059547 | Phase II | Nivolumab CTL-002 + Nivolumab | Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer | Recruiting | ITA | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06225596 | Phase II | Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | ARG | 5 |
NCT06263153 | Phase II | Durvalumab + Futibatinib | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | Recruiting | USA | 0 |
NCT06394570 | Phase Ib/II | Enfortumab vedotin-ejfv | Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer (STAR-EV) | Recruiting | USA | 0 |
NCT06434350 | Phase Ib/II | Enfortumab vedotin-ejfv | Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | Suspended | USA | 0 |
NCT06528483 | Phase II | Sacituzumab govitecan-hziy + Zimberelimab | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer (preSAVE) | Not yet recruiting | ITA | 0 |
NCT06630247 | Phase I | XL495 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |
NCT06682728 | Phase II | Nivolumab + Sacituzumab govitecan-hziy | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence | Recruiting | USA | 0 |